XenoPort, GlaxoSmithKline deal

XenoPort sent a notice to GlaxoSmithKline claiming that the pharma breached its contractual obligation to maximize sales of the partners' Horizant gabapentin enacarbil. GSK launched the transported prodrug of gabapentin last year in the U.S. for restless legs syndrome (RLS). The notice allows XenoPort to terminate the deal and regain rights after April 24, unless GSK has cured the breach prior to the date. GSK said in a statement that it believes it is acting in accordance with the terms of its agreement with XenoPort and will work with XenoPort to resolve all outstanding issues (see BioCentury, Aug. 1, 2011). ...